Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis

American Journal of Medicine

Volumn 108, Issue 1, 2000, Pages 65-72

  Jackson, Jeffrey L ^a   O'Malley, Patrick G ^b   Tomkins, Glen ^b   Balden, Erin ^b   Santoro, James ^c   Kroenke, Kurt ^d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

^d REGENSTRIEF INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATROPINE; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; MIANSERIN; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA BASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DROWSINESS; DRUG EFFICACY; FATIGUE; HEART PALPITATION; HUMAN; META ANALYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; RISK; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0033978273     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00299-5     Document Type: Review

References (70)

1. Drossman D.A., Thompson W.G. The irritable bowel syndrome review and a graduated multicomponent treatment approach . Ann Intern Med. 116:1992;1009-1016.
2. Drossman D.A., Zhiming L., Andruzzi E., et al. U.S. householder survey of functional gastrointestinal disorders prevalence, sociodemography, and health impact . Dig Dis Sci. 38:1993;1569-1580.
3. Lynn R.B., Friedman L.S. Irritable bowel syndrome. Managing the patient with abdominal pain and altered bowel habits. Med Clin North Am. 79:1995;373-390.
4. Irritable bowel syndrome. BMJ 1972;1:197-198.
5. Everhart J.E., Renault P.F. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 100:1991;998-1005.
6. Snape W.J., Carlson G.M., Cohen S. Colonic myoelectric activity in the irritable colon syndrome. Gastroenterology. 70:1976;236-330.
7. Mayer E.A., Raybould H.E. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology. 99:1990;1688-1704.
8. Harvey R.F., Read A.E. Effect of cholecystokinin on colonic motility and symptoms in patients with the irritable-bowel syndrome. Lancet. 1:1973;1-3.
9. Weston A.P., Biddle W.L., Bhatia P.S., Miner P.B. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 38:1993;1590-1595.
10. Whitehead W.E., Crowel M.D. Psychologic considerations in the irritable bowel syndrome. Gastroenterol Clin North Am. 20:1991;249-267.
11. Schwarz S.P., Blanchard E.B., Berreman C.F., et al. Psychological aspects of irritable bowel syndrome comparisons with inflammatory bowel disease and nonpatient controls . Behav Res Ther. 31:1993;297-304.
12. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials is blinding necessary? Control Clin Trials. 17:1996;1-12.
13. Stata Statistical Software Release 5.0 . 1995;Stata Corporation, College Station, Texas.
14. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:1997;209-216.
15. Galbraith R.F. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 7:1988;889-894.
16. Ysuf S., Peto R., Lewis J., et al. Beta blockade during and after myocardial infarction an overview of the randomized trials . Prog Cardiovasc Dis. 27:1985;335-371.
17. DerSimonian R., Laird N. Meta-analysis in clinical trials. Cont Clin Trials. 7:1986;177-188.
18. Rosenthal R. The file drawer problem and tolerance for null results. Psycholog Bull. 86:1979;638-641.
19. Loldrup D., Langemark M., Hansen H.J., et al. Clomipramine and mianserin in chronic idiopathic pain syndrome a placebo controlled study . Psychopharmacology. 99:1989;1-7.
20. Myren J., Loveland B., Larssen S.E., Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol. 19:1984;835-843.
21. Mertz H., Fass R., Kodner A., et al. Effect of amitryptiline on symptoms, sleep and visceral perception in patients with functional dyspepsia. Am J Gastroenterol. 93:1998;160-165.
22. Hefner J.D., Wilder R.M., Wilson I.D. Irritable colon and depression. Psychosomatics. 19:1978;540-547.
23. Tripathi B.M., Misra N.P., Gupta A.K. Evaluation of tricyclic compound (Timipramine) vis-a-vis placebo in irritable bowel syndrome. Double blind randomized study. JAPI. 31:1983;201-203.
24. Tanum L., Malt U.F. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol. 31:1996;318-325.
25. Greenbaum D.S., Mayle J.E., Vanegeren L.E., et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci. 32:1987;257-266.
26. Myren J., Lovland B., Larssen S.E., Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study. Scand J Gastroenterol. 17:1982;871-875.
27. Steinhart M.J., Wong P.Y., Zarr M.L. Therapeutic usefulness of amitriptyline in spastic colon syndrome. Intl J Psychiatry Med. 11:1981;45-57.
28. Vij J.G., Jiloha R.C., Kumar N., et al. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian J Psychiatry. 33:1991;243-246.
29. Rajagopalan M., Kurian G., John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol. 13:1998;738-741.
30. Lancaster-Smith M.J., Prout B.J., Pinto T., et al. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand. 66:1982;33-41.
31. Kazis L.E., Anderson J.J., Meenan R.F. Effect sizes for interpreting changes in health status. Med Care. 27:1989;S178-S189.
32. Mortensen P.B., Andersen J.R., Arffmann S., Krag E. Short-chain fatty acids and the irritable bowel syndrome the effect of wheat bran . Scand J Gastroenterol. 22:1987;185-192.
33. Cook I.J., Irvine E.J., Campbell D., et al. Effect of dietary fiber on symptoms and recto sigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. Gastroenterology. 98:1990;66-72.
34. Fowlie S., Eastwood M.A., Prescott R. Irritable bowel syndrome assessment of psychological disturbance and its influence on the response to fibre supplementation . Psychosom Res. 36:1992;175-180.
35. Snook J., Shepherd H.A. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 8:1994;511-514.
36. Lisker R., Solomons N.W., Perez Briceno R., Ramirez Mata M. Lactase and placebo in the management of the irritable bowel syndrome a double-blind, cross-over study . Am J Gastroenterol. 84:1989;627-756.
37. Lucey M.R., Clark M.L., Lowndes J., Dawson A.M. Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. Gut. 28:1987;221-225.
38. Kruis W., Weinzierl M., Schussler P., Holl J. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion. 34:1986;196-201.
39. Arffmann S., Andersen J.R., Hegnhoj J., et al. The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study. Scand J Gastroenterol. 20:1985;295-298.
40. Longstreth G.F., Fox D.D., Youkeles L., et al. Psyllium therapy in the irritable bowel syndrome. A double-blind trial. Ann Intern Med. 95:1981;53-56.
41. Poynard T., Naveau S., Mory B., Chaput J.C. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 8:1994;499-510.
42. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol. 130:(suppl):1987;81-84.
43. Efskind P.S., Bernklev T., Vatn M.H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 31:1996;463-468.
44. McQuay H., Carroll D., Jadad A.R., et al. Anticonvulsant drugs for management of pain a systematic review . BMJ. 311:1995;1047-1052.
45. Nash P., Gould S.R., Bernardo D.E. Peppermint oil does not relieve the pain of irritable bowel syndrome. Br J Clin Pract. 40:1986;292-293.
46. Bensoussan A., Talley N.J.H.J., Hing M., et al. Treatment of irritable bowel syndrome with Chinese herbal medicine a randomized controlled trial . JAMA. 280:1998;1585-1589.
47. Van Outryve M., Milo R., Toussaint J., Van Eeghem P. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome a placebo-controlled study of cisapride . J Clin Gastroenterol. 13:1991;49-57.
48. Noor N., Small P.K., Loudon M.A., et al. Effects of cisapride on symptoms and postcyabal small-bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol. 33:1998;605-611.
49. Farup P.G., Hovdenak N., Wetterhus S., et al. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol. 33:1998;128-131.
50. Schutze K., Brandstatter G., Dragosics B., et al. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther. 11:1997;387-394.
51. Talley N.J., McNeil D., Hayden A., Piper D.W. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcernon ulcer dyspepsia. Gastroenterology. 91:1986;149-156.
52. Nyren O., Adami H.O., Bates S., et al. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. NEJM. 4:1986;339-343.
53. Kairaluoma M.I., Hentilae R., Alavaikko M., et al. Sucralafate versus placebo in treatment of non-ulcer dyspepsia. Am J Med. 83:(3B):1987;51-55.
54. Drossman D.A., Leserman J., Nachman G., et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med. 113:1990;828-833.
55. Sandler R.S., Drossman D.A., Nathan H.P., McKee D.C. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. Gastroenterology. 87:1984;314-318.
56. Kroenke K., Jackson J.L., Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints clinical predictors and outcome . Am J Med. 103:1997;339-347.
57. Jackson J.L., O'Malley P.G., Kroenke K. Clinical predictors of mental disorders among medical outpatients, validation of the S4 model. Psychosomatics. 39:1998;431-436.
58. Alevizos B., Christodoulou G.N., Ioannidis C., et al. The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. Clin Neuropharmacol. 12:(suppl 2):1989;66-76.
59. Svedlund J., Sjodin I., Ottosson J.O., Dotevall G. Controlled study of psychotherapy in irritable bowel syndrome. Lancet. 2:1983;589-592.
60. Tomkins G.E., Jackson J.L., O'Malley P.G., et al. Treatment of chronic headache with anti-depressants a meta-analysis . J Gen Intern Med. 14:(suppl 2):1999;75.
61. Balden E.L., O'Malley P.G., Jackson J.L., et al. Use of antidepressants in the treatment of fibromyalgia a meta-analysis . J Gen Intern Med. 14:(suppl 2):1999;9.
62. Fishbain D.A., Cutler R.B., Rosomoff H.L., Rosomoff R.S. Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis. Psychosom Med. 60:1998;503-509.
63. O'Malley P.G., Jackson J.L., Tomkins G.E., et al. Efficacy of antidepressants for physical symptoms a critical review . J Gen Intern Med. 14:(suppl 2):1999;60.
64. Max M.B. Treatment of post-herpetic neuralgia antidepressants . Ann Neurol. 35:(suppl):1994;50-53.
65. Chalmers T.C. Effects of ascorbic acid on the common cold. Am J Med. 58:1973;532-536.
66. Malagelada J.R. Altered visceral sensation in functional dyspepsia and related syndromes. Mayer E.A., Raybould H.E. Basic and Clinical Aspects of Chronic Abdominal Pain. 1993;55-59 Elsevier, Amsterdam.
67. Mertz H., Fullerton S., Naliboff B., Mayer E.A. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut. 42:1998;814-822.
68. Argeus L., Svardsudd K., Nyren O., Tibblin G. Irritable bowel syndrome and dyspepsia in the general population overlap and lack of stability over time . Gastroenterology. 109:1995;671-680.
69. Fass R, Fullerton S, Diehl DL, et al. Sleep disturbance (SD) in patients with functional bowel disorders. Gastroenterology 1995;108:A596. Abstract.
70. Merta D.D., Fefer L., Sytnik B., et al. Sleep and duodenal motor activity in patients with severe non-ulcer dyspepsia. Gut. 35:1994;916-925.